Skip to content

SIGIL: Signal Interpretation and Analysis In Real Life Cardiac Arrhythmias

SIGIL: Signal Interpretation and Analysis In Real Life Cardiac Arrhythmias

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05508880
Acronym
SIGIL
Enrollment
80
Registered
2022-08-19
Start date
2019-10-30
Completion date
2023-05-30
Last updated
2022-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrhythmia

Brief summary

This study essentially consists of the prospective collection of mapping data derived from patients undergoing clinically indicated 3D mapping procedures. There is no intervention. The mapping data is used to construct and/or validate new activation mapping algorithms but will not be used to direct clinical treatment of the patient.

Detailed description

Cardiac arrhythmias are a common clinical problem in cardiology. Often, such arrhythmias can be effectively and permanently treated through catheter ablation. A key technology enabling the success of catheter ablation is activation mapping of cardiac arrhythmias. This refers to the construction of maps which depict the sequential activation of the cardiac chamber of interest. It is a fundamental electrophysiology technique, but at the same time, the principles behind activation map construction have not changed for decades. In brief, the way activation maps are constructed nowadays consists of the following steps: (i) Sequential acquisition of voltage signals throughout the cardiac chamber of interest, recording both the signal together with the location of the signal in 3D space (ii) Local activation time annotation of each of the acquired signals in relation to a so-called timing reference (iii) Depiction of the annotated activation time graphically as a so-called activation map, through which the mechanism of the arrhythmia can be understood and an appropriate ablation target chosen Following assignment of the LAT to each individual signal, the map is complete and can be used to discern the arrhythmia circuit to choose an appropriate ablation target. The objective of this study is to develop, refine and validate LAT-independent methods of activation map analysis using mapping data acquired from patients undergoing clinically indicated EP mapping and ablation procedures. Specific objectives: (i) Electrogram signature analysis. To use machine learning techniques to identify electrogram properties associated with specific conduction patterns. (ii) Intracardiac EGM summation. To integrate all acquired points into a global function that allows as precise a determination as possible of the period of isthmus conduction in re-entrant arrhythmias. (iii) Conduction velocity estimation. To algorithmically determine conduction velocity using proprietary techniques to wholly or partially reduce reliance on LAT annotation.This study aims to collect the electroanatomic 3D maps from patients to develop novel mapping algorithms, but this map data is not used to direct clinical treatment.

Interventions

None listed

Sponsors

Duke-NUS Graduate Medical School
CollaboratorOTHER
National Heart Centre Singapore
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Patient undergoing a clinically indicated 3D mapping procedure for a cardiac arrhythmia 2. Ability to provide informed consent

Exclusion criteria

* Patients who cannot provide informed consent will be excluded. Otherwise, there are no specific

Design outcomes

Primary

MeasureTime frameDescription
The overall objective of this study is to develop, refine and validate LAT-independent methods of activation map analysis using mapping data acquired from patients undergoing clinicallyindicated EP mapping and ablation procedures.2 yearsThis study aims to collect the electroanatomic 3D maps from patients to develop novel mapping algorithms, but this map data is not used to direct clinical treatment.

Countries

Singapore

Contacts

Primary ContactLum Luh Nah
lum.luh.nah@nhcs.com.sg6704 2265

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026